Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
Authors
Keywords
Adverse event reporting system, Immune-related adverse events, Immune checkpoint inhibitors, Data mining
Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 95, Issue -, Pages 107498
Publisher
Elsevier BV
Online
2021-03-14
DOI
10.1016/j.intimp.2021.107498
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab
- (2021) Yuichi Honma et al. INTERNAL MEDICINE
- Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
- (2020) Charles Dolladille et al. Journal for ImmunoTherapy of Cancer
- Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
- (2020) Hyun Ae Jung et al. LUNG CANCER
- Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia
- (2020) Ali Yılmaz et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
- (2020) Yuxin Sun et al. Asia-Pacific Journal of Clinical Oncology
- Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab
- (2020) Yoko Tsukita et al. EUROPEAN JOURNAL OF CANCER
- Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system
- (2020) Yingying Hu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
- (2020) Douglas B Johnson et al. LANCET ONCOLOGY
- Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
- (2020) Emanuel Raschi et al. Targeted Oncology
- Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study
- (2020) Naoto Okada et al. Scientific Reports
- Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors
- (2020) Karijn P. M. Suijkerbuijk et al. JAMA Oncology
- Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database
- (2020) Shiori Hasegawa et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
- (2020) Maria Stelmachowska-Banaś et al. Endocrine Connections
- Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
- (2019) K M Heinhuis et al. ANNALS OF ONCOLOGY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
- (2019) Yi Jiang et al. Therapeutics and Clinical Risk Management
- Hematologic Complications of Immune Checkpoint Inhibitors
- (2019) Elizabeth J. Davis et al. ONCOLOGIST
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
- (2019) Celeste Lebbé et al. JOURNAL OF CLINICAL ONCOLOGY
- Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
- (2019) Huan-huan Ji et al. CLINICAL DRUG INVESTIGATION
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
- (2019) Douglas B. Johnson et al. Journal for ImmunoTherapy of Cancer
- Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis
- (2019) Hang Xu et al. Drug Design Development and Therapy
- High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancer
- (2019) Mari Tone et al. Thoracic Cancer
- Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data
- (2019) Qianqian Fan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Drug‐induced sarcoidosis: an overview of the WHO pharmacovigilance database
- (2019) F. Cohen Aubart et al. JOURNAL OF INTERNAL MEDICINE
- Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
- (2019) Jingli Lu et al. Cancer Medicine
- The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
- (2019) Qing-Qing Chai et al. Frontiers in Pharmacology
- Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
- (2019) Yinghong Zhai et al. Journal for ImmunoTherapy of Cancer
- Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors
- (2019) Aurore Vozy et al. EUROPEAN JOURNAL OF CANCER
- The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease
- (2019) Naoki Nishiyama et al. International Journal of Clinical Oncology
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- (2018) Alexandra K. Rzepecki et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Sources of Safety Data and Statistical Strategies for Design and Analysis
- (2018) Rima Izem et al. Therapeutic Innovation & Regulatory Science
- Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- (2018) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Immune Checkpoint Inhibitor–Associated Myositis
- (2018) Céline Anquetil et al. CIRCULATION
- Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System
- (2018) Ippazio Cosimo Antonazzo et al. Expert Opinion On Drug Safety
- Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
- (2018) Estefanía Paula Juliá et al. Frontiers in Immunology
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Immune-related adverse events of immune checkpoint inhibitors: a brief review
- (2018) G. Myers Current Oncology
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- French Endocrine Society Guidance on endocrine side effects of immunotherapy
- (2018) F Castinetti et al. ENDOCRINE-RELATED CANCER
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- (2017) Myriam Delaunay et al. EUROPEAN RESPIRATORY JOURNAL
- Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
- (2017) Yasser M. Alatawi et al. Expert Opinion On Drug Safety
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
- (2017) Benjamin L. Maughan et al. Frontiers in Oncology
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC
- (2016) D.L. Gibbons et al. Journal of Thoracic Oncology
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immuno-Oncology: The Third Paradigm in Early Drug Development
- (2016) Juan Martin-Liberal et al. Targeted Oncology
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
- (2015) Jason J. Luke et al. Oncotarget
- Epidemiologic Survey of Japanese Patients with Idiopathic Pulmonary Fibrosis and Investigation of Ethnic Differences
- (2014) Motoki Natsuizaka et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Basis of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Japanese Patients
- (2013) Arata Azuma et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred
- (2011) S. Ono et al. EUROPEAN RESPIRATORY JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation